FAP - fibroblast activation protein alpha Gene

Also Known as FAPA; SIMP; DPPIV; FAPalpha

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 2191

About FAP

Cytogenetic location: 2q24.2 Genomic coordinates (GRCh38): 2:162,170,684-162,243,445 (from NCBI)

This gene has 13 transcripts (splice variants), 127 orthologues and 6 paralogues. Biased expression in endometrium (RPKM 7.5), gall bladder (RPKM 5.1) and 11 other tissues.

Summary

The protein encoded by this gene is a homodimeric integral membrane gelatinase belonging to the serine protease family. It is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. This protein is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2014]

FAP Products (2)

mRNA Protein Name
NM_001291807.3 NP_001278736.1 prolyl endopeptidase FAP isoform 2
NM_004460.5 NP_004451.2 prolyl endopeptidase FAP isoform 1

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence Referencias Source
enables dipeptidyl-peptidase activity IDA
IDA: Inferred from direct assay
10593948 GOA
enables endopeptidase activity IDA
IDA: Inferred from direct assay
17317851 GOA
enables identical protein binding IPI
IPI: Inferred from physical interaction
9065413 GOA
enables integrin binding IPI
IPI: Inferred from physical interaction
10455171 GOA
enables peptidase activity IDA
IDA: Inferred from direct assay
9688278 GOA
enables protease binding IPI
IPI: Inferred from physical interaction
17317851 GOA
enables protein binding IPI
IPI: Inferred from physical interaction
16651416 GOA
enables protein homodimerization activity IDA
IDA: Inferred from direct assay
10455171 GOA
enables serine-type endopeptidase activity IDA
IDA: Inferred from direct assay
10593948 GOA
enables serine-type peptidase activity IDA
IDA: Inferred from direct assay
16651416 GOA
enables serine-type peptidase activity IMP
IMP: Inferred from mutant phenotype
9065413 GOA
Biological Process GO Annotation Evidence Referencias Source
involved in endothelial cell migration IDA
IDA: Inferred from direct assay
16651416 GOA
involved in negative regulation of extracellular matrix disassembly IDA
IDA: Inferred from direct assay
16651416 GOA
involved in negative regulation of extracellular matrix organization IDA
IDA: Inferred from direct assay
10455171 GOA
involved in proteolysis IDA
IDA: Inferred from direct assay
10455171 GOA
involved in proteolysis IMP
IMP: Inferred from mutant phenotype
9065413 GOA
involved in proteolysis involved in protein catabolic process IDA
IDA: Inferred from direct assay
10593948 GOA
involved in regulation of collagen catabolic process IDA
IDA: Inferred from direct assay
10455171 GOA
Cellular Component GO Annotation Evidence Referencias Source
located in extracellular space IDA
IDA: Inferred from direct assay
17317851 GOA
located in lamellipodium IDA
IDA: Inferred from direct assay
9065413 GOA
part of peptidase complex IMP
IMP: Inferred from mutant phenotype
9065413 GOA
located in plasma membrane IDA
IDA: Inferred from direct assay
10593948 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

FAP Protein Structure

DPPIV_N

DPPIV_N: Dipeptidyl peptidase IV (DPP IV) N-terminal region (106 - 473)

Peptidase_S9

Peptidase_S9: Prolyl oligopeptidase family (555 - 757)

  • 0
  • 200
  • 400
  • 600
  • 760 a.a.
Protein Preferred Names Protein Names

prolyl endopeptidase FAP

  • 170 kDa melanoma membrane-bound gelatinase

FAP Protein-protein interaction Information

Type
Protein Name Protein ID Interactor Interactor Species Interactor ID Detection Method Referencias
Intra
FAP Q12884 VIP Homo sapiens P01282
Protease Assay
21314817
Intra
FAP Q12884 GCG Homo sapiens P01275
Protease Assay
21314817
Cross: Cross-species interaction Intra: Intraspecies interaction

Recombinant FAP Proteins

Referencia número Nombre del producto Accession Pureza
HY-P77521 FAP Protein, Human (Biotinylated, HEK293, His) Q12884-1 (L26-D760) ≥ 85%, as determined by reducing SDS-PAGE.
HY-P78121 FAP Protein, Human (Biotinylated, HEK293, His-Avi) Q12884-1 (L26-D760) ≥ 95%, as determined by Bis-Tris PAGE.

FAP Antibodies

Referencia número Nombre del producto Aplicación Reactivity
HY-P81345 FAP Antibody (YA1090) WB, IHC-P Human
HY-P81345A FAP Antibody (YA1090)(PBS only) WB, IHC-P Human
HY-P81697 FAP Antibody (YA1442) IHC-P, FC, ELISA Human
HY-P84520 FAP Antibody (YA4217) IHC-P, FC, ELISA Human
HY-P84520A FAP Antibody (YA4217)(PBS only) IHC-P, FC, ELISA Human
HY-P86341 FAP Antibody (YA6033) WB, IHC-P, ICC/IF, IP, ELISA Human
HY-P86673 FAP Antibody (YA6365) WB Human
HY-P86673A FAP Antibody (YA6365)(PBS only) WB Human

Related Diseases

Diseases Alias
Breast Ductal Carcinoma

  • Ductal Breast Carcinoma

  • Duct Carcinoma

  • Carcinoma, Ductal

  • Mammary Ductal Carcinoma

  • Ductal Carcinoma
Melanoma

  • Malignant Melanoma

  • Cutaneous Melanoma

  • Naevocarcinoma

  • Malignant Melanomas
Glioma
Colorectal Cancer

  • Colon Cancer

  • Colorectal Carcinoma

  • Colon Carcinoma

  • Colorectal Cancer, Susceptibility To

  • Carcinoma Of Colon

  • CRC

  • Colorectal Cancer With Chromosomal Instability, Somatic

  • Colon Cancer, Somatic

  • Colon Cancer, Susceptibility To

  • Colonic Neoplasms

  • Colorectal Neoplasms

  • Colorectal Cancer, Somatic

  • Colon Cancer, Advanced, Somatic

  • Colonic Carcinoma

  • Colorectal Carcinomas

  • Colon Cancers

  • Colorectal Cancers

  • Cancer, Colorectal, Somatic

  • Cancer, Colon

  • Cancer, Colorectal, Susceptibility To

  • Colorectal Neoplasm

  • Colonic Neoplasm

  • Malignant Tumor Of Colon
Ovarian Cancer

  • Ovarian Carcinoma

  • Ovarian Neoplasm

  • Malignant Tumour Of Ovary

  • Cancer Of The Ovary

  • Epithelial Ovarian Cancer

  • Neoplasm Of Ovary

  • Ovarian Neoplasms

  • Ovarian Cancers

  • Malignant Neoplasm Of Ovary

  • Primary Malignant Neoplasm Of Ovary

  • Ovarian Cancer, Somatic

  • Malignant Ovarian Tumor

  • Ovary Neoplasm

  • Primary Ovarian Cancer

  • Tumor Of The Ovary

  • Malignant Neoplasm Of The Ovary

  • Malignant Tumor Of The Ovary

  • Ovarian Malignant Tumor

  • OC

  • Ovarian Carcinomas

  • Cancer, Ovarian

  • Cancer Of Ovary

  • Ovary Cancer

  • Ca Ovary
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (5)
Referencia número Nombre del producto Efecto
Pureza Phase
HY-P3392A Zilganersen sodium Inhibitor 91.43% Phase 3
HY-137331 FAPI-46 99.02% Phase 2
HY-172317 AZD2389 Inhibitor 99.65% Phase 2
HY-147057A Rofapitide tetraxetan acetate / Phase 1
HY-177083 Faridoxorubicin Substrate / Phase 1
Inhibitory Antibodies (1)
Referencia número Nombre del producto Efecto
Pureza Phase
HY-P99269 Sibrotuzumab 99.05% Phase 2

Pre-clinical Phase

Bioactive Molecules (74)
Referencia número Nombre del producto
Efecto
Pureza
Rare Diseases
HY-147057 Rofapitide tetraxetan 99.89% Unkown
HY-128643 FAPI-4 99.47% Unkown
HY-100684 UAMC-1110 Inhibitor 99.51% Unkown
HY-101801 Ac-Gly-BoroPro 98.0% Unkown
HY-145983 Suc-Gly-Pro-AMC 99.85% Unkown
HY-147173 FAPI-74 99.84% Unkown
HY-153552A NH2-UAMC1110 TFA Inhibitor 99.98% Unkown
HY-145938 OncoFAP 99.77% Unkown
HY-P10944 Unlabeled FXX489 Ligand 98.52% Unkown
HY-160289 ARI-3144 Substrate 99.72% Unkown
HY-P10131 3BP-3940 99.49% Unkown
HY-164725 FAPI-mFS Inhibitor 98.71% Unkown
HY-164316 FT-FAPI-12_9 99.07% Unkown
HY-125366 ARI-3099 Inhibitor 99.95% Unkown
HY-47979 FAP-IN-2 Inhibitor 99.93% Unkown
HY-136641 NOTA-FAPI Inhibitor 99.66% Unkown
HY-P3441A 3BP-4089 TFA Inhibitor 99.27% Unkown
HY-D2363 DOTA.SA.FAPi TFA Inhibitor 99.26% Unkown
HY-139401 FAPI-34 Ligand 98.04% Unkown
HY-P10945 FAP targeting peptide for FXX489 99.49% Unkown
HY-161074 PNT6555 96.55% Unkown
HY-164364A DOTAGA.(SA.FAPi)2 TFA Inhibitor 97.51% Unkown
HY-177435 FAPI-800CW Inhibitor 99.40% Unkown
HY-175350 OncoFAP-GlyPro-MMAE Ligand 99.71% Unkown
HY-47979A FAP-IN-2 TFA Inhibitor 99.92% Unkown
HY-153552 NH2-UAMC1110 Inhibitor 99.86% Unkown
HY-P10945B Cys-FAP targeting peptide for FXX489 TFA 95.77% Unkown
HY-175613 DOTA-ALB-02 Ligand 99.71% Unkown
HY-173374 DOTAGA-FAP-2286-ALB Inhibitor 99.29% Unkown
HY-164567 SID 125240931 98.75% Unkown
HY-183513 L-Ala-BPA Substrate / Unkown
HY-128642 FAPI-2 98.94% Unkown
HY-164316A FT-FAPI-12_9 TFA 99.48% Unkown
HY-D2281 FAP Ligand 2 / Unkown
HY-159771 FAP6-19 Ligand / Unkown
HY-159768A DOTAGA.Glu.(FAPi)2 Ligand / Unkown
HY-175612 DOTA-ALB-01 Ligand / Unkown
HY-172137 FAPI-FUSCC-07 Ligand / Unkown
HY-164364B DOTAGA.(SA.FAPi)2 analogue TFA Inhibitor 99.38% Unkown
HY-175685 FAP-IN-7 Inhibitor / Unkown
HY-176958 OncoFAP-EN-DOTAGA Inhibitor / Unkown
HY-P3392C Zilganersen sodium scrambled negative control Inhibitor / Unkown
HY-177459 DOTA-2P(FAPI)2 Inhibitor / Unkown
HY-146182 FSDD3I / Unkown
HY-182272 FAP-IN-9 Inhibitor / Unkown
HY-175330 FAP-IN-6 Inhibitor / Unkown
HY-186190 I-FAPI-04 prodrug-1 Inhibitor / Unkown
HY-146181 FSDD1I / Unkown
HY-P10945A Cys-FAP targeting peptide for FXX489 / Unkown
HY-182250 BR103354 Inhibitor / Unkown
HY-173319 FAP-IN-5 Inhibitor / Unkown
HY-178981 FAP-IN-8 Inhibitor / Unkown
HY-128642A FAPI-2 TFA 98.05% Unkown
HY-P3441 3BP-4089 Inhibitor 99.27% Unkown
HY-158326 FAP-IN-4 Inhibitor / Unkown
HY-159934 QI-18 Inhibitor / Unkown
HY-103323 Fas C-Terminal Tripeptide Inhibitor / Unkown
HY-148361 Fluorogen binding modulator-1 / Unkown
HY-175353 TriOncoFAP-GlyPro-MMAE / Unkown
HY-146180 FSDD0I / Unkown
HY-175322 FAPI-P8PN Inhibitor / Unkown
HY-182434 CL 118326 Antagonist / Unkown
HY-183796 GFAP/NF-κB/APOE/NLRP3-IN-1 Inhibitor / Unkown
HY-170779 DOTA-NI-FAPI-04 Inhibitor / Unkown
HY-149860 FAP-IN-1 Inhibitor / Unkown
HY-P11602 DOTA-C1-FAP-2286 / Unkown
HY-P3392 Zilganersen 91.43% Unkown
HY-174421 FAPI-JNU Ligand / Unkown
HY-161262 SB03178 Inhibitor / Unkown
HY-P11599 NOTA-SP2A-FAPT Ligand / Unkown
HY-181494 FAPI-X5 Inhibitor / Unkown
HY-181580 FAP Ligand 3 Ligand / Unkown
HY-163079 AlF-PD-FAPI / Unkown
HY-W668749 3BP-3580 Inhibitor / Unkown
Inhibitory Antibodies (2)
Referencia número Nombre del producto
Efecto
Pureza
Rare Diseases
HY-P990245 Anti-Mouse FAP Antibody (73.3) Inhibitor 95.00% Unkown
HY-P991995 OMTX005 Inhibitor 98.44% Unkown

Orthologs Information

Species Symbol Source ID
Rattus norvegicus FAP RGD RGD:621253
Bos taurus FAP VGNC VGNC:28862
Canis familiaris FAP VGNC VGNC:40727
Felis catus FAP VGNC VGNC:62146
Macaca mulatta FAP VGNC VGNC:72613
Mus musculus FAP MGD MGI:109608
Others FAP NCBI